Musculoskeletal

Takayasu arteritis: diagnosis and management

Clinical Overview and When to Suspect Takayasu Arteritis

— Young women age 15–40, female:male ~9:1

— Higher prevalence in Asian, Latin American, Middle Eastern populations, but seen worldwide

— Often called "pulseless disease" historically

— T-cell and macrophage-mediated panarteritis of the media and adventitia

— Leads to intimal proliferation → luminal narrowing → downstream ischemia and collateral formation

— Late phase: fibrosis, occlusion, or aneurysmal dilation

— Young woman with arm claudication, syncope, dizziness, or visual changes

— Unequal BP between arms (>10 mm Hg), diminished/absent pulses, carotid or subclavian bruits

— Refractory hypertension in a young patient (renal artery stenosis)

— Constitutional symptoms (fever, weight loss, fatigue, arthralgias) plus elevated ESR/CRP without infection

— Stroke, TIA, or angina/MI in a woman under 40 with no traditional risk factors

— Pre-pulseless / systemic phase: nonspecific inflammation (months–years)

— Pulseless / occlusive phase: vascular insufficiency from established stenoses

— TA: age <40, aorta + branches, Asian/Latina predominance

— GCA: age >50, temporal/cranial branches, white predominance

— Histology is nearly identical — age is the discriminator

Board pearl: Any young woman with asymmetric arm BPs, an unexplained bruit, and elevated ESR/CRP should trigger immediate consideration of Takayasu arteritis — order CTA or MRA of the aorta and branches, not just a duplex of one vessel.

Definition: Takayasu arteritis (TA) is a chronic, granulomatous large-vessel vasculitis preferentially involving the aorta and its major branches (subclavian, carotid, renal, mesenteric, pulmonary), producing stenosis, occlusion, dilation, or aneurysm.

Epidemiology — the classic stem:

Pathophysiology:

When to suspect on Step 3:

Two clinical phases (overlap commonly):

Differentiation from giant cell arteritis (GCA):

Presentation Patterns and Key History

— Low-grade fever, night sweats, weight loss, malaise, fatigue

— Arthralgias/myalgias, occasionally erythema nodosum or pyoderma gangrenosum

— Misdiagnosed as viral syndrome, fibromyalgia, or "FUO"

— Subclavian/axillary (most common, ~90%): arm claudication on exertion, cool hand, Raynaud-like symptoms, asymmetric BP

— Common carotid/vertebral: dizziness, syncope, visual blurring or amaurosis, TIA/stroke, carotidynia (tender carotid)

— Renal artery: renovascular hypertension — often the presenting feature in young patients; may be severe and refractory

— Abdominal aorta/mesenteric: postprandial abdominal angina, weight loss, diarrhea

— Coronary ostia (5–10%): angina, MI, sudden cardiac death in a young woman

— Pulmonary artery (~50% on imaging): dyspnea, hemoptysis, pulmonary HTN

— Aortic root: aortic regurgitation murmur from root dilation

— "Does one arm tire or hurt with use?" (claudication)

— "Have you been told your BP is hard to read or different in each arm?"

— Headaches, jaw pain, visual loss → overlap with cranial features

— Pregnancy history (TA worsens pregnancy outcomes)

— Family history of vasculitis or autoimmune disease

Key distinction: A young woman presenting with hypertension + headache + arm fatigue is not "anxiety" — measure BP in both arms and both legs. A >10 mm Hg interarm difference in this context is Takayasu until proven otherwise. The same patient with pulsatile temporal headache and jaw claudication at age 65 is GCA — age, not symptom, drives the label.

Step 3 management: Document four-extremity BPs at the index visit and at every follow-up — this is both a diagnostic and a disease-activity monitoring tool.

Constitutional ("pre-pulseless") symptoms — present in ~50%, often missed for months:

Vascular/ischemic symptoms — by territory:

Key history questions on Step 3:

Course: relapsing-remitting in 50%, monophasic in ~20%, progressive in ~25%.

Physical Exam Findings and Hemodynamic Assessment

— Four-extremity blood pressures: interarm difference >10 mm Hg is a major criterion

— BP may be unobtainable in an affected arm ("pulseless"); use the unaffected arm or leg

— Central aortic pressure may be far higher than the cuff reading — risk of unrecognized severe HTN driving stroke, LVH, renal injury

— Always measure leg BP if both arms involved

— Diminished or absent radial, brachial, carotid, or femoral pulses

— Asymmetric pulse amplitude

— Carotid, subclavian, supraclavicular, abdominal, renal, femoral bruits

— Multiple bruits in a young patient is highly suggestive

— Diastolic murmur of aortic regurgitation (root dilation)

— Signs of heart failure from HTN, AR, or coronary involvement

— Loud P2 if pulmonary artery involvement

— Erythema nodosum, livedo, ulcers (rare)

— Hypertensive or ischemic retinopathy ("Takayasu retinopathy" — arteriovenous anastomoses)

— Focal deficits from stroke/TIA, orthostatic syncope from carotid disease

— Cuff BP in an affected limb underestimates true central BP → use the highest reliably measurable extremity

— Severe bilateral subclavian disease can mask hypertensive emergency — patient appears normotensive while end-organs are damaged

— Pulse pressure widening suggests AR or aortic stiffness

CCS pearl: On any young woman admitted with stroke, MI, or hypertensive crisis, order bilateral arm + leg BPs and a full vascular auscultation as part of the initial exam — these are free, fast, and diagnostically pivotal. Missing this step is a classic Step 3 trap that leads to delayed diagnosis.

Board pearl: The combination of absent radial pulse + carotid bruit + young woman + elevated ESR is a near-pathognomonic exam triad for Takayasu.

Vital signs / hemodynamics — the cornerstone:

Pulses:

Auscultation — bruits in unusual places:

Cardiac:

Skin/eye:

Neurologic:

Hemodynamic pearls for the boards:

Diagnostic Workup — Initial Labs and Imaging

— ESR elevated in 70–80% during active disease (often >50 mm/hr)

— CRP elevated — more sensitive for tracking activity than ESR

— Normocytic anemia of chronic disease, mild thrombocytosis, hypoalbuminemia

— Mildly elevated LFTs possible

— ANCA negative, ANA usually negative — helps exclude small-vessel vasculitis and SLE

— Cryoglobulins, hepatitis serologies negative

— Pregnancy test in any reproductive-age woman before imaging/immunosuppression

— BMP, urinalysis (look for renovascular HTN signs — bland sediment, normal Cr early)

— ECG: LVH from HTN, ischemic changes if coronary ostial disease

— TTE: aortic root dilation, AR, LV function, pulmonary pressures

— CT angiography (CTA) of chest/abdomen/pelvis with neck vessels: shows wall thickening, stenosis, dilation, occlusion across the whole arterial tree in one study

— MR angiography (MRA) preferred when:

– Patient is young/female (avoids radiation)

– Repeat imaging anticipated for monitoring

– Pregnancy concerns (without gadolinium if possible)

— Findings: "macaroni sign" — long, smooth, concentric wall thickening of the aorta and branches; long-segment stenoses with collaterals; aneurysms

— Useful for carotid/subclavian — shows homogeneous, circumferential wall thickening ("halo sign"), but limited for thoracic aorta

— ESR/CRP useful but imperfect — up to 50% with active disease have normal labs; imaging often shows progression despite "quiet" labs

Step 3 management: When you suspect TA, order whole-body large-vessel imaging (CTA or MRA from neck to pelvis) — do not stop at a carotid duplex. Limited imaging misses the diagnosis because TA is multi-territorial.

Key distinction: ESR/CRP support but do not exclude TA — imaging drives diagnosis and follow-up.

Initial labs (nonspecific but supportive):

Renal/cardiac workup:

First-line vascular imaging — the diagnostic test:

Duplex ultrasound:

Activity markers:

Diagnostic Workup — Advanced and Confirmatory Studies

— Score ≥5 of: female sex, angina, arm/leg claudication, vascular bruit, reduced pulse, BP asymmetry, plus imaging-based items (number of arterial territories involved, paired artery involvement, abdominal aorta + renal/mesenteric involvement)

— Classification, not diagnosis — clinical judgment still rules

— Historical gold standard; now reserved for:

– Planning revascularization

– Measuring central aortic pressure when cuff BPs are unreliable

— Findings: smooth, tapered, long-segment stenoses; "rat-tail" tapering; collaterals

— Detects active arterial wall inflammation (vascular FDG uptake ≥ liver)

— Most useful in:

– Early disease when CT/MR show no structural change

– Distinguishing active inflammation from established fibrotic stenosis when ESR/CRP are inconclusive

– Monitoring response in difficult cases

— Limitations: atherosclerosis can mimic; steroids reduce sensitivity within days

— Shows mural edema and post-contrast enhancement → active inflammation

— Preferred for serial monitoring (no radiation)

— Rarely obtained — vessels are inaccessible; diagnosis is imaging-based

— If obtained at surgery: granulomatous panarteritis with giant cells, indistinguishable from GCA

— Syphilis serology (RPR), TB (IGRA) — both can cause aortitis

— IgG4 levels — IgG4-related aortitis mimics TA

— Blood cultures if fever — exclude infective aortitis

— HLA-B52 association is recognized but not used clinically

Board pearl: A young woman with imaging-confirmed long-segment aortic wall thickening, negative ANCA/ANA, normal IgG4, negative TB and syphilis, and elevated CRP = Takayasu arteritis. PET-CT is the answer when the question asks how to distinguish active inflammation from chronic fibrosis in a patient with persistent symptoms but normal ESR/CRP.

ACR/EULAR 2022 classification criteria (entry: age ≤60, imaging evidence of vasculitis):

Conventional (catheter) angiography:

FDG-PET / PET-CT:

MRI with vessel-wall imaging (black-blood sequences):

Biopsy:

Workup to exclude mimics:

Risk Stratification and First-Line Management Logic

— Is the disease active (needs immunosuppression)?

— Is there critical ischemia or structural damage (needs revascularization)?

— What comorbid risks (HTN, pregnancy, atherosclerosis) need parallel control?

— New constitutional symptoms (fever, malaise)

— Elevated ESR

— Features of vascular ischemia (claudication, bruit, absent pulse, BP asymmetry)

— Typical angiographic features (new lesion on imaging)

— Mild: constitutional symptoms ± single non-critical stenosis

— Moderate: multiple stenoses, claudication, controlled HTN

— Severe/critical: critical organ ischemia (cerebral, coronary, renal, mesenteric), rapidly expanding aneurysm, severe AR, dissection

— Induce and maintain remission (clinical + imaging + biomarkers)

— Prevent vascular damage progression

— Minimize glucocorticoid toxicity with steroid-sparing agents

— Control cardiovascular risk factors aggressively (HTN, lipids, smoking, glucose)

— BP target generally <130/80, but measure in the highest-reading limb (often a leg if both subclavians stenosed)

— ACE inhibitors/ARBs help renovascular HTN but caution if bilateral RAS — monitor Cr and K

— Statin if atherosclerotic risk or known coronary involvement

— Low-dose aspirin considered in patients with vascular stenoses or coronary/cerebral involvement

Step 3 management: Once TA is diagnosed, start high-dose glucocorticoids promptly AND simultaneously plan a steroid-sparing agent at the index visit — don't wait for steroid failure to add one. This is the modern EULAR/ACR-aligned approach.

Key distinction: Active inflammation → immunosuppression first. Critical fixed stenosis without active inflammation → revascularization, ideally during a quiet inflammatory window.

Frame management around three questions:

Disease activity assessment (NIH/Kerr criteria — ≥2 = active):

Severity stratification:

Treatment goals:

Cardiovascular comorbid management runs in parallel:

Multidisciplinary care: rheumatology (lead), vascular surgery, cardiology, interventional radiology, MFM if pregnant.

Pharmacotherapy — First-Line Drug Regimen

— Prednisone 1 mg/kg/day (max ~60 mg/day) PO for 4 weeks

— IV methylprednisolone pulse (500–1000 mg × 3 days) for severe disease: critical ischemia, neurologic involvement, rapidly progressive aneurysm

— Taper: reduce by ~10 mg/wk to 20 mg, then slower; aim for ≤10 mg/day by 3–6 months, off by 12 months when possible

— Pre-treatment: bone density, glucose, lipids, hepatitis B/C, TB screen

— Bone protection from day 1: calcium 1000–1200 mg, vitamin D 800 IU, bisphosphonate if anticipated steroid use ≥3 months at ≥7.5 mg/day

— PJP prophylaxis (TMP-SMX) if on ≥20 mg prednisone-equivalent for ≥4 weeks combined with another immunosuppressant

— Methotrexate 15–25 mg PO/SC weekly + folic acid 1 mg daily — first-line in many centers

— Azathioprine 2 mg/kg/day — check TPMT before starting

— Mycophenolate mofetil 1–2 g BID — useful in renal involvement or AZA intolerance

— Leflunomide — alternative

— TNF inhibitors (infliximab, adalimumab) — strong evidence; screen TB and hepatitis B before

— Tocilizumab (anti–IL-6R) — increasingly used; may lower ESR/CRP independent of disease activity, complicating monitoring

— Rituximab less effective than in ANCA vasculitis; reserved for refractory cases

— JAK inhibitors — emerging

— Aspirin 81 mg if stenotic vascular disease, coronary or cerebrovascular involvement

— Statin per ASCVD risk

— Aggressive BP control with ACEI/ARB (monitor for bilateral RAS), CCBs

Board pearl: Tocilizumab normalizes inflammatory markers even when arterial inflammation persists — on tocilizumab, monitor disease activity with imaging (MRA or PET), not just ESR/CRP.

Step 3 management: Plan the steroid taper at the time you write the first prednisone order and document the bone, GI, and infection prophylaxis bundle the same day.

Glucocorticoids — induction backbone:

Steroid-sparing / remission-maintenance agents — start early (often at diagnosis):

Biologics (refractory/relapsing disease):

Adjuncts:

Procedures — Revascularization and Invasive Management

— Renovascular hypertension uncontrolled on ≥3 drugs

— Critical cerebrovascular stenosis (carotid/vertebral) with TIA, stroke, or syncope

— Coronary ostial stenosis with ischemia

— Limb-threatening ischemia or disabling claudication

— Mesenteric ischemia

— Aortic aneurysm ≥5.5 cm (or rapidly expanding) or aortic regurgitation with LV dysfunction

— Aortic coarctation-like lesions with HTN

— Whenever possible, perform revascularization during an inactive/quiescent inflammatory phase (normal CRP, stable imaging)

— Operating during active inflammation → higher rates of restenosis, anastomotic aneurysm, graft failure

— If urgent intervention needed during active disease, continue immunosuppression perioperatively

— Open surgical bypass generally preferred over endovascular for:

– Long-segment lesions

– Aortic involvement

– Aneurysms / AR (root/valve repair or replacement)

– Better long-term patency in TA than stenting

— Endovascular (angioplasty ± stent):

– Short, focal lesions

– High surgical risk patients

— Higher restenosis rate than in atherosclerosis; bare-metal stents generally preferred over drug-eluting for peripheral TA lesions

— Renal artery: angioplasty often first; surgical bypass for long lesions

— Coronary ostial disease: CABG often outperforms PCI in TA

— Continue immunosuppression

— Stress-dose steroids if on chronic prednisone

— Aspirin perioperatively for arterial reconstructions

— Long-term imaging surveillance of grafts (restenosis is common)

CCS pearl: In a young woman with refractory HTN and bilateral renal artery stenosis from TA, first induce remission with steroids + steroid-sparing agent and optimize BP medically; defer renal artery angioplasty until CRP is normal and imaging is stable, unless ischemic nephropathy is progressive.

Key distinction: Atherosclerotic renal artery stenosis → often stent. Takayasu renal artery stenosis → suppress inflammation first, then intervene; bypass often beats stent for durability.

Indications for revascularization:

Timing — the critical principle:

Modality choice:

Perioperative principles:

Special Populations — Elderly and Renal/Hepatic Impairment

— TA classically begins before age 40; new onset >60 is giant cell arteritis by definition under most criteria

— A patient diagnosed at 25 may present at 60 with chronic damage (stenoses, AR, HTN) rather than active inflammation

— Distinguish active vasculitis from burnt-out fibrotic disease — PET/MR vessel-wall imaging helps

— Elderly TA patients carry dual risk: chronic vasculitic damage + superimposed atherosclerosis — both contribute to events

— Premature atherosclerosis is common — aggressive statin, BP, glycemic, and smoking control

— Reassess aortic root and aneurysms with imaging every 1–2 years lifelong

— Causes: renovascular HTN, ischemic nephropathy, NSAID exposure, drug toxicity

— ACEI/ARB: effective for renovascular HTN but contraindicated/cautioned in bilateral RAS or solitary functioning kidney with RAS — monitor Cr (>30% rise → stop) and K

— Methotrexate: avoid if CrCl <30; reduce dose 30–50 if CrCl 30–60; risk of myelosuppression

— Mycophenolate: generally safe in CKD; dose-adjust if severe

— Azathioprine: caution with allopurinol; reduce in renal impairment

— Contrast imaging: iodinated contrast risk in CKD — prefer non-contrast MRA or duplex for surveillance; gadolinium avoided if eGFR <30

— NSAIDs avoid in patients with renovascular disease

— Methotrexate hepatotoxic — baseline and serial LFTs; avoid alcohol; contraindicated in active liver disease

— Azathioprine — hepatotoxicity, cholestasis; monitor LFTs

— Leflunomide — hepatotoxic; long half-life, cholestyramine washout

— Screen HBV/HCV before any biologic or immunosuppressant — risk of HBV reactivation; give entecavir prophylaxis if HBsAg+

Step 3 management: In a TA patient with bilateral renal artery stenosis and HTN, start a CCB or alpha/beta blocker first, add ACEI/ARB cautiously with Cr and K rechecked in 1–2 weeks, and stop if Cr rises >30%.

"Elderly" Takayasu — does it exist?

Cardiovascular risk in aging TA patients:

Renal impairment:

Hepatic impairment:

Steroid-related issues amplified in elderly: osteoporosis, diabetes, cataracts, infection — minimize cumulative dose.

Special Populations — Pregnancy and Pediatrics

— TA disproportionately affects women of reproductive age — pre-conception planning is critical

— Ideal: conceive during stable remission ≥6 months on pregnancy-compatible regimen

— Maternal risks: worsened hypertension, preeclampsia (up to 30–50%), heart failure, aortic dissection, cerebrovascular events

— Fetal risks: IUGR, preterm delivery, fetal loss — risk correlates with maternal HTN and disease activity

— Safe / continue: prednisone (lowest effective dose), azathioprine, hydroxychloroquine, low-dose aspirin (recommended for preeclampsia prevention starting 12–16 wk)

— Compatible: TNF inhibitors (especially certolizumab — minimal placental transfer); infliximab/adalimumab acceptable, limit in 3rd trimester

— Contraindicated: methotrexate, mycophenolate, leflunomide, cyclophosphamide — stop 3–6 months before conception; counsel contraception

— ACEI/ARBs contraindicated — switch to labetalol, nifedipine, methyldopa, hydralazine

— Four-extremity BP every visit (cuff BPs often unreliable — consider central pressure assessment)

— Serial growth ultrasounds, MFM co-management

— Cardiology assessment of aortic root and AR

— Imaging surveillance: MRA without gadolinium if needed

— Vaginal delivery preferred in stable disease; assisted second stage to limit Valsalva if aortic aneurysm/AR

— C-section for obstetric or severe cardiovascular indications

— Epidural BP changes must be managed cautiously when central BP poorly correlates with cuff

— Second most common large-vessel vasculitis in children (after Kawasaki sequelae)

— Presents with HTN, fever, weight loss, headache — often misdiagnosed

— Renovascular HTN dominates pediatric presentation

— Management mirrors adults: steroids + steroid-sparing agent (often MTX or MMF); TNF/tocilizumab for refractory

— Monitor growth, puberty, bone health closely

Board pearl: A pregnant young woman with refractory HTN, an interarm BP difference, and a carotid bruit = TA — start labetalol/nifedipine, low-dose aspirin, continue prednisone + azathioprine, and co-manage with MFM and rheumatology.

Pregnancy in Takayasu arteritis:

Medications in pregnancy:

Monitoring in pregnancy:

Delivery:

Pediatric Takayasu:

Complications and Adverse Outcomes

— Hypertension (refractory, renovascular) — most prevalent, drives downstream damage

— Stroke / TIA from carotid or vertebral stenosis

— Myocardial infarction from coronary ostial disease — young women with MI and no atherosclerosis risk factors

— Aortic aneurysm (thoracic > abdominal), pseudoaneurysm

— Aortic dissection — uncommon but catastrophic

— Aortic regurgitation from root dilation → heart failure

— Mesenteric ischemia, ischemic nephropathy, limb ischemia

— Pulmonary artery stenosis → pulmonary hypertension, hemoptysis

— Heart failure — multifactorial (HTN, AR, ischemia, myocarditis)

— Increased risk of arrhythmia, sudden cardiac death

— Restenosis after intervention (markedly higher than in atherosclerosis)

— Anastomotic pseudoaneurysm at surgical sites

— Glucocorticoid toxicity: osteoporosis/fractures, diabetes, hypertension, weight gain, cataracts, glaucoma, infection, AVN, mood changes, adrenal suppression

— Immunosuppressant toxicity: cytopenias, hepatotoxicity, infection (including opportunistic — TB, HBV reactivation, PJP)

— Biologics: infections, infusion reactions, TB reactivation (screen with IGRA and CXR before starting), HBV reactivation

— Vaccine considerations: complete inactivated vaccines (influenza, pneumococcal, COVID-19, HBV); avoid live vaccines while immunosuppressed

— Chronic disease in young women — depression, anxiety, work disability, fertility concerns

— Cosmetic effects of steroids affect adherence

— 10-year survival 80–90% in modern era

— Worse prognosis with: progressive course, major complications at diagnosis, severe HTN, AR, aneurysm, retinopathy

Step 3 management: Every TA visit should include: BP in highest-reading limb, weight, glucose, bone health assessment, vaccination status review, depression screen, and review of current immunosuppression and prophylaxis.

Key distinction: A 32-year-old TA patient with chest pain isn't anxiety — work up coronary ostial stenosis and AR with ECG, troponin, and TTE/CTA.

Vascular complications:

Cardiac:

Disease-progression complications:

Treatment-related complications:

Psychosocial:

Mortality:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Aortic dissection — emergent CT angiography, BP control with esmolol + nitroprusside/nicardipine, cardiothoracic surgery

— Acute stroke or evolving TIA — stroke protocol; tPA decisions must consider vasculitis-related bleeding risk

— Acute MI in young woman — coronary angiography; suspect ostial TA lesion; involve interventional cardiology + rheumatology

— Hypertensive emergency with end-organ damage — IV nicardipine/labetalol; measure BP in highest reliable extremity, watch for falsely normal cuff BP due to subclavian disease

— Mesenteric ischemia — surgical and vascular consultation

— Critical limb ischemia

— Rapidly progressive heart failure from severe AR

— CNS vasculitis with altered mental status — pulse methylprednisolone

— New diagnosis with active systemic inflammation requiring IV pulse steroids

— Severe refractory HTN requiring IV titration

— Need for inpatient diagnostic workup (angiography, planning revascularization)

— Infection in an immunosuppressed patient

— Rheumatology — at diagnosis and any flare

— Vascular surgery / interventional radiology — for any planned revascularization or aneurysm

— Cardiology / cardiothoracic surgery — AR, aortic root dilation, coronary involvement

— Maternal-fetal medicine — pregnancy

— Nephrology — renovascular HTN or CKD

— Ophthalmology — visual symptoms, Takayasu retinopathy

— Coordinate revascularization during disease quiescence when feasible

— Stress-dose hydrocortisone for any patient on ≥5 mg prednisone-equivalent for >3 weeks undergoing major surgery

— Continue immunosuppression perioperatively unless infection

CCS pearl: In a 28-year-old with refractory hypertension and a "normal" BP in the right arm — always measure the left arm and a leg before declaring her normotensive. A missed central hypertensive crisis in masked TA is a high-yield Step 3 safety scenario.

Step 3 management: New severe TA at diagnosis warrants inpatient admission for IV pulse methylprednisolone, multidisciplinary planning, and baseline whole-body imaging rather than discharge with oral prednisone.

Immediate ICU / emergent admission:

Urgent inpatient admission (not necessarily ICU):

Specialty consultation triggers:

Surgical/perioperative escalation rules:

Key Differentials — Same-Category (Vasculitis) Causes

— Age >50 (entry criterion), peaks 70s

— Cranial features: temporal headache, jaw claudication, scalp tenderness, vision loss (AION)

— Polymyalgia rheumatica overlap (~50%)

— Also affects aorta and branches (~25% — "large-vessel GCA")

— Temporal artery biopsy diagnostic; histology indistinguishable from TA

— Treatment overlaps: high-dose prednisone, tocilizumab FDA-approved

— Key separator from TA: age, ethnicity, cranial features

— Recurrent oral and genital ulcers, uveitis, skin lesions, pathergy

— Can cause large-vessel disease — pulmonary artery aneurysms, venous thrombosis (unusual in TA)

— Mediterranean, Middle Eastern, Asian distribution

— Treat with colchicine, azathioprine, TNF inhibitors

— Interstitial keratitis + audiovestibular dysfunction (Meniere-like)

— Aortitis, AR in ~10%

— Young adults; treat with steroids

— Periaortitis, retroperitoneal fibrosis, salivary/lacrimal gland enlargement, pancreatitis

— Elevated serum IgG4, dense lymphoplasmacytic infiltrate with storiform fibrosis

— Responds to steroids and rituximab

— Medium-vessel vasculitis (not large) — renal microaneurysms, mesenteric, skin nodules, mononeuritis multiplex

— Often hepatitis B–associated

— Spares pulmonary arteries; doesn't cause large-vessel stenoses

— Small-vessel; lung, kidney (RPGN), sinuses, peripheral nerve

— ANCA positive; not large-vessel imaging findings

— Young male smoker, distal limb ischemia, no large-vessel aortic disease

Board pearl: A 70-year-old with new headache, jaw claudication, and ESR 90 = GCA. A 25-year-old with arm claudication, BP asymmetry, and ESR 60 = TA. Age is the single best discriminator because histology is identical.

Key distinction: Behçet causes pulmonary artery aneurysms and venous thrombosis — TA causes stenoses and occlusions.

Giant cell arteritis (GCA):

Behçet disease:

Cogan syndrome:

IgG4-related disease:

Polyarteritis nodosa (PAN):

ANCA-associated vasculitides (GPA, MPA, EGPA):

Buerger disease (thromboangiitis obliterans):

Key Differentials — Other-Category Causes

— Older patients with traditional risk factors (HTN, DM, hyperlipidemia, smoking)

— Eccentric, calcified, ostial plaques rather than long, smooth, concentric wall thickening

— No systemic inflammation; ESR/CRP normal

— Treat with risk factor modification, statins, antiplatelets, revascularization as needed

— Young women, often with HTN — strong TA mimic

— Classic "string of beads" appearance, mid-to-distal renal and carotid arteries

— Spares aorta proper; no systemic inflammation, normal ESR/CRP

— Treat with ACEI/ARB; angioplasty for refractory HTN; screen for intracranial aneurysms

— Congenital; presents with HTN, upper-extremity hypertension, lower-extremity hypotension, radio-femoral delay, rib notching on CXR

— Bicuspid aortic valve association

— Imaging shows discrete narrowing distal to left subclavian — distinct from diffuse TA pattern

— Acute, severe pain; risk factors (Marfan, Ehlers–Danlos vascular type, HTN, bicuspid valve)

— Imaging shows intimal flap or crescentic wall hematoma

— Syphilis — ascending aorta, vasa vasorum endarteritis, "tree-bark" intima, AR; positive RPR/FTA

— Mycotic aneurysm — Salmonella, Staph; saccular, irregular; positive blood cultures

— Tuberculous aortitis — rare; from contiguous lymph nodes

— Marfan, Loeys–Dietz, vascular Ehlers–Danlos, Turner — aneurysms and dissection without wall inflammation

— Prior neck/chest radiation; carotid/subclavian stenoses; no systemic inflammation

— Drug history; reversible

Step 3 management: Young woman + renovascular HTN → distinguish TA vs. FMD: CTA/MRA. Long, smooth, concentric thickening with elevated CRP → TA. Beaded mid-renal artery in a non-inflamed patient → FMD.

Board pearl: Always check RPR and TB before labeling new aortitis as TA — treatable infectious mimics must be excluded.

Atherosclerotic large-vessel disease:

Fibromuscular dysplasia (FMD):

Coarctation of the aorta:

Aortic dissection / intramural hematoma:

Infectious aortitis:

Genetic aortopathies:

Radiation-induced vasculopathy:

Ergot or sympathomimetic vasospasm:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Maintain remission with steroid-sparing agent (MTX, AZA, MMF, or biologic)

— Goal: prednisone ≤5–7.5 mg/day by 6–12 months, ideally off

— Treat flares with steroid re-escalation ± switch in steroid-sparing agent or escalation to biologic (TNFi or tocilizumab)

— BP target <130/80 (measured in the highest-reading extremity); preferred agents: ACEI/ARB (with bilateral RAS caution), CCBs, beta-blockers if AR or coronary disease

— Statin for any patient with documented vascular stenosis or coronary involvement

— Aspirin 81 mg for vascular stenoses, prior MI/stroke, or coronary involvement

— Smoking cessation — counseling at every visit

— Diabetes screen annually (steroid-induced)

— Weight, diet, exercise counseling tailored to claudication

— Calcium 1000–1200 mg + vitamin D 800–1000 IU daily

— DEXA at baseline and every 1–2 years on chronic steroids

— Bisphosphonate if FRAX risk elevated or anticipated steroids ≥7.5 mg/day for ≥3 months

— Glucose, lipids, A1c monitoring

— Vaccines before immunosuppression when possible: influenza (annual), pneumococcal PCV20 or PCV15+PPSV23, shingles (recombinant Shingrix — non-live, OK on immunosuppression), HBV, HPV, COVID-19, Tdap

— Avoid live vaccines (MMR, varicella, yellow fever, intranasal flu) while immunosuppressed

— TB screening (IGRA) before biologics; treat LTBI

— HBV screening; antiviral prophylaxis if HBsAg+ and starting biologics/rituximab

— PJP prophylaxis (TMP-SMX) if combined immunosuppression with prednisone ≥20 mg ≥4 weeks

— Effective contraception while on teratogenic drugs (MTX, MMF, leflunomide)

— Pre-conception planning during quiet disease

Step 3 management: At every TA discharge or follow-up, document the "long-term TA bundle": immunosuppression plan + BP target + statin + ASA decision + bone protection + vaccines + contraception + imaging schedule.

Long-term immunosuppression plan:

Cardiovascular secondary prevention bundle:

Bone and metabolic protection:

Infection prevention:

Reproductive counseling:

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Active disease or new diagnosis: every 1–3 months

— Stable remission: every 3–6 months, then yearly when long-stable

— Post-revascularization: 1 month, 3 months, then every 6–12 months indefinitely

— Four-extremity BPs, all major pulses, full vascular auscultation

— Symptom review: claudication, neurologic, visual, chest, abdominal symptoms

— Steroid side-effect screen; medication adherence

— Weight, glucose, BP, depression screen

— ESR and CRP every visit — track activity (with the tocilizumab caveat — markers unreliable)

— CBC, CMP, LFTs every 1–3 months on DMARDs/biologics

— A1c, lipid panel yearly (more often on steroids)

— Urinalysis for renovascular disease

— MRA of involved territories every 6–12 months during early disease, then annually when stable

— TTE annually if AR, root dilation, or coronary involvement

— PET-CT for clinical–biomarker discordance or suspected smoldering inflammation

— Lifelong surveillance — even quiescent disease can progress silently

— Supervised exercise improves claudication tolerance and cardiovascular fitness

— Cardiac rehab post-MI/CABG; vascular rehab post-revascularization

— Avoid heavy isometric exercise if significant aortic aneurysm or AR

— Recognize warning signs: sudden vision loss, focal weakness, chest pain, severe back pain (dissection), new severe abdominal pain

— Medical alert ID noting TA, BP measurement preferred limb, current immunosuppression, steroid dependence

— Avoid NSAIDs (renal, BP, GI)

— Sun protection on hydroxychloroquine/MTX

— Mental health support; peer/disease-specific resources

— Clear written plan, med reconciliation, and rheumatology follow-up within 1–2 weeks of any hospitalization

— Communicate BP-measurement preferences and stress-dose steroid needs to all providers — including dentists, ED, surgeons

CCS pearl: A patient on tocilizumab with normal ESR/CRP but new claudication is active until proven otherwise on imaging — order MRA or PET, do not reassure based on labs alone.

Visit cadence:

At every visit — clinical:

Laboratory monitoring:

Imaging surveillance:

Rehab and exercise:

Patient counseling:

Transitions of care (Step 3 emphasis):

Ethical, Legal, and Patient Safety Considerations

— Discuss risks: infection, malignancy (long-term), infertility (cyclophosphamide), teratogenicity (MTX, MMF, leflunomide), osteoporosis, steroid toxicity

— In a young woman of childbearing age: document discussion of contraception, teratogenicity, and pre-conception planning before prescribing MTX or MMF — this is a Step 3 testable consent edge case

— Patient retains decision-making authority; counsel risks but respect choice

— Coordinate with MFM; if patient declines recommended medication changes, document shared decision-making

— Steroid taper miscommunication → adrenal crisis after surgery, illness, or abrupt discontinuation

— Always write the explicit taper schedule on discharge and notify outpatient provider

— Provide stress-dose steroid instructions and a wallet card for patients on chronic ≥5 mg prednisone for >3 weeks

— Avoid live vaccines in immunosuppressed patients — check before any vaccine order

— Check drug interactions (azathioprine + allopurinol → severe pancytopenia; MTX + TMP-SMX → bone marrow suppression)

— NSAID avoidance counseling — patients often self-medicate

— Routine cuff BP in TA can be falsely reassuring — communicate the preferred limb for BP to every provider, including outpatient nurses, ED staff, and anesthesia

— Wrong-limb BP leading to undetected hypertensive crisis is a sentinel-event-class error

— Document functional impairment for employment accommodations and disability paperwork honestly and objectively

— Structured transition program improves adherence and outcomes; begin transition planning by age 14–16

— Reproductive and mental health discussions in adolescents — follow state minor-consent laws

— TA disproportionately affects ethnic minorities and women — ensure equitable access to biologics, imaging, and specialty care

Step 3 management: Before initiating methotrexate in a 26-year-old woman with TA, document: negative pregnancy test, effective contraception plan, alcohol counseling, vaccination review (including avoidance of live vaccines), and risk/benefit discussion — this bundle is the testable consent standard.

Informed consent for chronic immunosuppression:

Pregnancy and reproductive autonomy:

Transitions of care — the high-risk failure mode:

Medication reconciliation safety:

Patient safety in BP measurement:

Disability and work:

Adolescent transition (pediatric → adult):

Confidentiality:

Research and equity:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Young woman + arm claudication + BP asymmetry + elevated ESR/CRP + long-segment smooth aortic wall thickening on MRA = Takayasu arteritis — start prednisone and a steroid-sparing agent at diagnosis.

Demographics: young woman, 15–40, Asian/Latin American/Middle Eastern predominance, F:M ~9:1.

"Pulseless disease" — diminished or absent peripheral pulses in stenotic limb.

Interarm BP difference >10 mm Hg = major classification criterion.

Most commonly involved vessel: subclavian artery (~90%); left > right.

Pulmonary artery involvement in ~50% on imaging — distinguishes TA from most other vasculitides except Behçet.

Coronary involvement = ostial — think TA in young woman with MI and no atherosclerotic risk factors.

Renovascular HTN — the most common cause of severe HTN in TA; bilateral RAS possible.

Aortic regurgitation from root dilation — diastolic murmur in a young woman.

"Macaroni sign" = long, smooth, concentric wall thickening of aorta on MRA/CTA.

"Halo sign" on vessel ultrasound = circumferential mural thickening.

Histology identical to GCA — granulomatous panarteritis with giant cells; age distinguishes.

ACR/EULAR 2022 entry rule: age ≤60 with imaging evidence of vasculitis.

HLA-B52 association recognized but not used clinically.

Numano angiographic classification: types I–V based on arterial territories involved.

NIH/Kerr criteria define active disease — clinical + ESR + ischemia + new angiographic lesion.

Treatment backbone: high-dose prednisone + steroid-sparing agent (MTX/AZA/MMF) early.

Refractory disease: TNF inhibitors or tocilizumab — both effective.

Tocilizumab caveat: normalizes ESR/CRP independent of disease activity — monitor by imaging.

Revascularization preferentially performed during disease quiescence; bypass > stent for durability.

Pregnancy: preeclampsia risk 30–50%; continue prednisone, AZA; stop MTX/MMF before conception.

Mortality: 10-year survival 80–90%; worse with HTN, AR, aneurysm, retinopathy.

Vaccines: complete inactivated series before immunosuppression; avoid live vaccines thereafter.

Always rule out infectious aortitis (syphilis, TB) and IgG4-related aortitis before labeling TA.

Board Question Stem Patterns

— 24-year-old woman with months of fatigue, low-grade fever, weight loss; now arm tires when reaching overhead. Exam: absent left radial pulse, left supraclavicular bruit, BP 150/90 right arm, 90/60 left arm. ESR 78, CRP 32. Next step: CTA/MRA of aorta and branches. Diagnosis: TA.

— 28-year-old woman with chest pain, troponin elevated, no atherosclerotic risk factors. ESR elevated. Coronary angiography shows left main ostial stenosis, aortic wall thickening on CT. Diagnosis: TA with coronary ostial involvement. Management: stabilize ACS, high-dose steroids, multidisciplinary planning; CABG often preferred over PCI.

— 30-year-old woman on 4 antihypertensives, Cr stable, abdominal bruit. Next test: renal MRA → bilateral long-segment renal artery stenosis with aortic wall thickening. Diagnosis: TA. Management: induce remission first, then consider revascularization.

— 27-year-old with known TA, currently on MTX, planning pregnancy. Best step: stop MTX ≥3 months before conception, switch to azathioprine, continue low-dose prednisone, start ASA 81 mg at 12 weeks, MFM co-management.

— 32-year-old vs. 72-year-old with similar imaging findings — age determines TA vs. GCA.

— TA patient on tocilizumab with new claudication but normal ESR/CRP. Next step: MRA or PET to assess vascular activity — markers are unreliable on IL-6 blockade.

— Long, smooth, concentric wall thickening = TA; beaded mid-renal artery = FMD; calcified eccentric plaque = atherosclerosis.

— TA patient in ED, right-arm BP 110/70 but patient symptomatic with headache and blurry vision. Action: measure left arm and a leg; if 200/110, treat as hypertensive emergency despite "normal" right arm.

— TA patient on prednisone 10 mg/day undergoing cholecystectomy. Order: stress-dose hydrocortisone perioperatively; continue maintenance immunosuppression.

— Aortitis in 40-year-old man with ascending aorta involvement and AR. Check RPR/FTA — syphilitic aortitis must be excluded before TA label.

Step 3 management: Each stem reduces to: confirm with imaging, induce with steroids + steroid-sparing agent, control BP in the right limb, plan procedures during quiescence, and avoid drug/imaging/vaccine pitfalls.

Stem 1 — Classic presentation:

Stem 2 — MI in a young woman:

Stem 3 — Refractory HTN:

Stem 4 — Pregnancy:

Stem 5 — Distinguishing from GCA:

Stem 6 — Tocilizumab pitfall:

Stem 7 — Imaging pattern:

Stem 8 — Safety pitfall (CCS):

Stem 9 — Perioperative:

Stem 10 — Mimic exclusion:

One-Line Recap

Takayasu arteritis is a granulomatous large-vessel vasculitis of young women that causes stenosis of the aorta and its major branches — diagnose with whole-body CTA or MRA, treat with high-dose glucocorticoids plus an early steroid-sparing agent (methotrexate, azathioprine, MMF, or TNF/IL-6 biologic), revascularize during disease quiescence, and aggressively manage hypertension and cardiovascular risk lifelong.

Board pearl: When a Step 3 vignette pairs a young woman, asymmetric pulses or BPs, and elevated inflammatory markers, the answer is almost always Takayasu — confirm with MRA from neck to pelvis, treat with steroids + steroid-sparing agent at diagnosis, and remember that age is the single best discriminator between Takayasu and the histologically identical giant cell arteritis.

Diagnose: young woman + interarm BP difference >10 mm Hg + bruit + elevated ESR/CRP + long, smooth, concentric arterial wall thickening on CTA/MRA — exclude syphilis, TB, IgG4-related disease.

Treat: prednisone 1 mg/kg/day (IV pulse if severe) with bone, GI, and infection prophylaxis; add MTX/AZA/MMF early; escalate to TNF inhibitor or tocilizumab for refractory/relapsing disease; remember tocilizumab masks ESR/CRP — monitor by imaging.

Intervene: revascularize for critical ischemia, refractory renovascular HTN, severe AR, or aneurysm — prefer surgical bypass over endovascular and schedule during inactive disease whenever possible.

Protect: measure BP in the highest-reading extremity, target <130/80, statin and aspirin for vascular disease, vaccinate before immunosuppression (avoid live vaccines after), counsel teratogenic-drug contraception, co-manage pregnancies with MFM, and surveil with annual MRA and TTE for life.